424 related articles for article (PubMed ID: 20602988)
1. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease.
Abratt VR; Reid SJ
Adv Appl Microbiol; 2010; 72():63-87. PubMed ID: 20602988
[TBL] [Abstract][Full Text] [Related]
2. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
Tavasoli S; Alebouyeh M; Naji M; Shakiba Majd G; Shabani Nashtaei M; Broumandnia N; Basiri A
BJU Int; 2020 Jan; 125(1):133-143. PubMed ID: 31145528
[TBL] [Abstract][Full Text] [Related]
3. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB
J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activity of probiotics-oxalate degradation.
Murphy C; Murphy S; O'Brien F; O'Donoghue M; Boileau T; Sunvold G; Reinhart G; Kiely B; Shanahan F; O'Mahony L
Vet Microbiol; 2009 Apr; 136(1-2):100-7. PubMed ID: 19028028
[TBL] [Abstract][Full Text] [Related]
5. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease.
Siva S; Barrack ER; Reddy GP; Thamilselvan V; Thamilselvan S; Menon M; Bhandari M
BJU Int; 2009 Jan; 103(1):18-21. PubMed ID: 19021605
[TBL] [Abstract][Full Text] [Related]
6. Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus.
Turroni S; Vitali B; Bendazzoli C; Candela M; Gotti R; Federici F; Pirovano F; Brigidi P
J Appl Microbiol; 2007 Nov; 103(5):1600-9. PubMed ID: 17953571
[TBL] [Abstract][Full Text] [Related]
7. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans?
Mogna L; Pane M; Nicola S; Raiteri E
J Clin Gastroenterol; 2014; 48 Suppl 1():S91-5. PubMed ID: 25291139
[TBL] [Abstract][Full Text] [Related]
8. Stable expression of the oxc and frc genes from Oxalobacter formigenes in human embryo kidney 293 cells: implications for gene therapy of hyperoxaluria.
Ye ZQ; Kong DB; Chen ZQ; Yao LF; Guo H; Yu X; Liu GL; Yang WM
Int J Mol Med; 2007 Oct; 20(4):521-6. PubMed ID: 17786282
[TBL] [Abstract][Full Text] [Related]
9. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration.
Campieri C; Campieri M; Bertuzzi V; Swennen E; Matteuzzi D; Stefoni S; Pirovano F; Centi C; Ulisse S; Famularo G; De Simone C
Kidney Int; 2001 Sep; 60(3):1097-105. PubMed ID: 11532105
[TBL] [Abstract][Full Text] [Related]
10. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?
Hoppe B; von Unruh G; Laube N; Hesse A; Sidhu H
Urol Res; 2005 Nov; 33(5):372-5. PubMed ID: 16284877
[TBL] [Abstract][Full Text] [Related]
11. Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?
Peck AB; Canales BK; Nguyen CQ
Urolithiasis; 2016 Feb; 44(1):45-50. PubMed ID: 26645869
[TBL] [Abstract][Full Text] [Related]
12. Role of gut microbiota against calcium oxalate.
Sadaf H; Raza SI; Hassan SW
Microb Pathog; 2017 Aug; 109():287-291. PubMed ID: 28624518
[TBL] [Abstract][Full Text] [Related]
13. Diversity of faecal oxalate-degrading bacteria in black and white South African study groups: insights into understanding the rarity of urolithiasis in the black group.
Magwira CA; Kullin B; Lewandowski S; Rodgers A; Reid SJ; Abratt VR
J Appl Microbiol; 2012 Aug; 113(2):418-28. PubMed ID: 22616725
[TBL] [Abstract][Full Text] [Related]
14. [Effect of oral lactosucrose supplementation on human enteric oxalate-degrading bacteria].
Takei K; Akakura K; Ueda T; Mikami K; Ito H
Hinyokika Kiyo; 2006 Sep; 52(9):687-91. PubMed ID: 17040052
[TBL] [Abstract][Full Text] [Related]
15. Effect of a Probiotic Supplement Containing Lactobacillus Acidophilus and Bifidobacterium Animalis Lactis on Urine Oxalate in Calcium Stone Formers with Hyperoxaluria: A Randomized, Placebo-controlled, Double-blind and In-vitro Trial.
Tavasoli S; Jalali S; Naji M; Borumandnia N; Shakiba Majd G; Basiri A; Khosravi Darani K; Karamad D; Tajabadi-Ebrahimi M; Taheri M
Urol J; 2021 Jun; 19(3):179-188. PubMed ID: 34129232
[TBL] [Abstract][Full Text] [Related]
16. Oxalate-degrading Providencia rettgeri isolated from human stools.
Hokama S; Toma C; Iwanaga M; Morozumi M; Sugaya K; Ogawa Y
Int J Urol; 2005 Jun; 12(6):533-8. PubMed ID: 15985073
[TBL] [Abstract][Full Text] [Related]
17. Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats.
Paul E; Albert A; Ponnusamy S; Mishra SR; Vignesh AG; Sivakumar SM; Sivasamy G; Sadasivam SG
Microbiol Res; 2018 Oct; 215():65-75. PubMed ID: 30172310
[TBL] [Abstract][Full Text] [Related]
18. Development of an Innovative Method by Optimizing qPCR Technique for Isolating and Determining Oxalobacter Formigenes Microbial Load in the Stool of Patients with Urolithiasis.
Jafari GA; Fotouhi Ardakani R; Akhavan Sepahi M; Nowroozi J; Soltanpour MS
Iran J Kidney Dis; 2021 May; 15(3):190-198. PubMed ID: 33994378
[TBL] [Abstract][Full Text] [Related]
19. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
Troxel SA; Sidhu H; Kaul P; Low RK
J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
[TBL] [Abstract][Full Text] [Related]
20. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis.
Hoppe B; von Unruh GE; Blank G; Rietschel E; Sidhu H; Laube N; Hesse A
Am J Kidney Dis; 2005 Sep; 46(3):440-5. PubMed ID: 16129205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
